References
- 1. Karwacki MW, Wozniak W. Neurofibromatosis: an inborn genetic disorder with susceptibility to neoplasia. Med Wieku Rozwoj 2006;10(3 Pt 2):923-48.
- 2. Zoller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Goteborg, Sweden. Acta Derm Venereol 1995;75(2):136-40.
- 3. Wang Z, Liu Y. Research update and recent developments in the management of scoliosis in neurofibromatosis type 1; Orthopedics2010;33(5):335-41.10.3928/01477447-20100329-2020507037
- 4. Sorensen SAMJ, Nielsen A. Long-term follow-up of von Recklinghausen neurofibromatosis: survival and malignant neoplams. N Engl J Med 1986;17:1010-5.
- 5. Khosrotehrani K, Bastuji-Garin S, Zeller J, Revuz J, Wolkenstein P.Clinical risk factors for mortality in patients with neurofibromatosis 1: a cohort study of 378 patients. Arch Dermatol 2003;139:187-91.10.1001/archderm.139.2.18712588224
- 6. Walker LTD, Easton D, Ponder B, Ponder M, Frayling I, Baralle D. A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer 2006;95(2):233-8.10.1038/sj.bjc.6603227236061616786042
- 7. Upadhyaya M, Ruggieri M, Maynard J, et al. Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum Genet 1998;102(5):591-7.10.1007/s0043900507469654211
- 8. Riva P, Corrado L, Natacci F, et al. NF1 microdeletion syndrome: refined FISH characterization of sporadic and familial deletions with locus-specific probes. Am J Hum Genet 2000;66:100-9.10.1086/302709128831510631140
- 9. Jett K, Friedman JM. Clinical and genetic aspects of neurofibromatosis. Genet Med 2010;12(1):1-11. 10.1097/GIM.0b013e3181bf15e320027112